AMRX vs INDV
AMRX: A diversified biopharmaceutical company providing a broad range of generic, branded, and specialty medicines alongside pharmaceutical distribution services. INDV: Indivior is a specialty pharmaceutical company dedicated to developing and marketing treatments for substance use disorders and mental health conditions, anchored by its flagship injectable product, SUBLOCADE.
Side-by-side fundamentals
| Metric | AMRX | INDV | Edge |
|---|---|---|---|
| Price as of 2026-07-31 close | $18.32 | $40.03 | |
| Market cap as of 2026-08-03 | $5.8B | $4.9B | |
| P/E as of 2026-08-03 | 49.12 | 19.43 | INDV lower |
| PEG as of 2026-08-03 | 2.85 | 0.84 | INDV lower |
| Net margin as of 2026-08-03 | +4.0% | +19.4% | INDV higher |
| Gross margin as of 2026-08-03 | +38.7% | +81.3% | INDV higher |
| Operating margin as of 2026-08-03 | +14.3% | +24.4% | INDV higher |
| ROE as of 2026-08-03 | -34.9% | +159.1% | INDV higher |
| ROA as of 2026-08-03 | +3.4% | +19.1% | INDV higher |
| Debt / equity as of 2026-08-03 | 136.58 | 27.90 | INDV lower |
| Revenue growth (YoY) as of 2026-08-03 | +7.6% | +10.3% | INDV higher |
| Revenue CAGR (3y) SEC XBRL | +10.9% | +11.2% | INDV higher |
| Beta as of 2026-08-03 | 0.88 | 0.53 | |
| 1-year return as of 2026-07-31 close | +134.3% | +133.5% | AMRX higher |
Fundamentals: market data, as of 2026-08-03. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-31.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.